Phase Ia/Ib dose-escalation study of ABL001 (CTX-009, bispecific antibody targeting DLL4 and VEGF-A) as a single agent in patients with advanced solid tumors

Authors
Category Primary study
JournalMolecular Cancer Therapeutics
Year 2021
This article has no abstract
Epistemonikos ID: 004debe7a1fb6ceb18f15d1cbf89663775d0d244
First added on: Feb 14, 2025